Japan's Mitsubishi Tanabe expected to have fast-production flu vaccine ready by 2019

Japan's Mitsubishi Tanabe is moving forward with a flu vaccine that is produced by implanting genetic material from the flu virus into tobacco leaves, which then produce flulike particles containing antigens to provoke an immune response. The key benefit of the tobacco manufacturing process is that it requires only one month to produce a vaccine, compared to the 6 months required to produce a traditional egg-based jab. The company hopes to get the vaccine to market by 2018 or 2019. More from FierceVaccines

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.